Bli medlem
Bli medlem

Du är här


Spago: Invitation to presentation of Spago Nanomedical AB's year-end report for 2016

Spago Nanomedical AB publishes its year-end report for 2016 on
February 14.

For this reason the company invites investors, analysts, and media to
a presentation on Tuesday, February 14 at 9:30 CET, at Nyhetsbyrån
Direkt, Jakobsbergsgatan 13 in Stockholm. CEO Mats Hansen presents on
the company development and respond to questions. Send notification
of participation to

The presentation will also be broadcasted in real time online and can
be viewed via Spago Nanomedical's home page
where it also will be available afterwards.

For further information, contact Mats Hansen, CEO Spago Nanomedical
AB, +46 767 764294,

Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials
for cancer diagnostics and therapy. The company's development
activities are primarily focused on the cancer selective MRI-contrast
agent SpagoPix, and the Tumorad®-project for cancer selective
radionuclide therapy of cancer. The business concept of Spago
Nanomedical is to develop projects from explorative to regulatory
preclinical or early clinical phase, and then out-license or enter
partnership for continued development of the projects to market
launch. Spago Nanomedical collaborates with well-established and
reputable patent consultants to continuously strengthen the
intellectual property protection of the projects.

The aim of SpagoPix is to improve cancer diagnostics using magnetic
resonance imaging (MRI) by facilitating early discovery of tumors and
metastases. Early discovery improves the chances of efficient
treatment and survival of cancer patients. Tumorad® is a further
development of the company's proprietary nanoparticles with the
purpose of delivering radionuclides for tumor selective radiation
therapy of cancer. Access to new therapies is essential for effective
treatment of many forms of cancer.

For further information, see


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.